Genmab A/S (NASDAQ:GMAB) Coverage Initiated by Analysts at Redburn Atlantic

Analysts at Redburn Atlantic assumed coverage on shares of Genmab A/S (NASDAQ:GMAB) in a note issued to investors on Tuesday, Briefing.com reports. The firm set a “buy” rating on the stock.

GMAB has been the topic of several other research reports. Truist Financial lowered their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Friday, September 20th. BTIG Research lifted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $23.43 on Tuesday. The stock has a market cap of $15.49 billion, a PE ratio of 19.53, a price-to-earnings-growth ratio of 0.73 and a beta of 0.98. The firm has a fifty day moving average price of $26.55 and a 200 day moving average price of $27.53. Genmab A/S has a 1 year low of $23.24 and a 1 year high of $35.88.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). The company had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. As a group, equities analysts expect that Genmab A/S will post 1.27 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently made changes to their positions in GMAB. Capital International Investors grew its stake in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after acquiring an additional 315,355 shares in the last quarter. Harding Loevner LP grew its position in shares of Genmab A/S by 2.7% in the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after purchasing an additional 85,665 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after purchasing an additional 103,859 shares during the last quarter. DDD Partners LLC purchased a new position in Genmab A/S during the second quarter worth approximately $8,860,000. Finally, Cubist Systematic Strategies LLC boosted its stake in Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after buying an additional 145,689 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.